Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • My watchlists
  • Help
  • Contact us
  • Log in to HL Account

Regeneron Pharmaceuticals Inc (REGN) Common Stock USD0.001

Sell:$517.93 Buy:$518.50 Change: $0.02 (0.00%)
NASDAQ:0.87%
Market closed |  Prices as at close on 15 January 2021 | Switch to live prices |
Sell:$517.93
Buy:$518.50
Change: $0.02 (0.00%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 15 January 2021 | Switch to live prices |
Sell:$517.93
Buy:$518.50
Change: $0.02 (0.00%)
Market closed |  Prices as at close on 15 January 2021 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases. The Company's marketed products include EYLEA (aflibercept) Injection, Praluent (alirocumab) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use, Kevzara (sarilumab) Solution for Subcutaneous Injection and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. As of December 31, 2016, the Company had 16 product candidates in clinical development, which consisted of a Trap-based clinical program and 15 fully human monoclonal antibody product candidates.

Contact details

Address:
777 Old Saw Mill River Rd
TARRYTOWN
10591-6717
United States
Telephone:
+1 (914) 8477000
Website:
https://www.regeneron.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
REGN
ISIN:
US75886F1075
Market cap:
$54.62 billion
Shares in issue:
106.71 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • P. Roy Vagelos
    Chairman of the Board, Director
  • Leonard Schleifer
    President, Chief Executive Officer, Director
  • George Yancopoulos
    President, Chief Scientific Officer, Director
  • Robert Landry
    Chief Financial Officer, Executive Vice President - Finance
  • Joseph LaRosa
    Executive Vice President, General Counsel, Secretary
  • Daniel Van Plew
    Executive Vice President, General Manager - Industrial Operations and Product Supply
  • Andrew Murphy
    Executive Vice President - Research
  • Neil Stahl
    Executive Vice President - Research and Development
  • Marion McCourt
    Senior Vice President - Commercial
  • Christopher Fenimore
    Vice President, Controller

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.